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S U M M A R Y
Background: Laboratory support is needed to conﬁrm the clinical diagnosis of Lyme neuroborreliosis
(LNB). Antibodies to Borrelia-speciﬁc proteins have been used to improve serological diagnostics.
The aims of this study were to assess the occurrence of antibodies to decorin-binding protein B (DbpB)
in serum and cerebrospinal ﬂuid (CSF) in children with LNB and to evaluate the performance of DbpB
variants in the diagnosis of LNB in children.
Methods: Serum and CSF sample pairs were available from 57 children evaluated for LNB. Based on the
presence of anti-ﬂagella antibodies and pleocytosis in the CSF, patients were divided into three different
groups: conﬁrmed LNB (n = 24), possible LNB (n = 16), and non LNB (n = 17). Recombinant DbpBs from
three Borrelia burgdorferi sensu lato species – Borrelia burgdorferi sensu stricto, Borrelia garinii, and
Borrelia afzelii – were used in an ELISA to detect IgG antibodies.
Results: The sensitivity of variant recombinant DbpBs in serum and CSF samples varied between 0%
and 46% and between 0% and 42%, respectively. In CSF, the most sensitive antigen was the DbpB variant
from B. garinii.
Conclusions: Serum or CSF antibodies to DbpB do not appear to be beneﬁcial in the laboratory diagnosis
of LNB in children.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Lyme disease (LD) is an infectious disease transmitted via a tick
bite. It is caused by a group of Borrelia burgdorferi sensu lato
spirochaetes. At least ﬁve Borrelia species (B. burgdorferi sensu
stricto, B. afzelii, B. garinii, B. spielmanii, and B. bavariensis) may
cause LD in Europe.1 Due to the genotypic and phenotypic
heterogeneity of the B. burgdorferi sensu lato species, clinical
symptoms vary.2 In the disseminated stage of the disease, one of
the most common manifestations, especially in Europe, is* Corresponding author.
E-mail address: Heidi.Sillanpaa@helsinki.ﬁ (H. Sillanpa¨a¨).
http://dx.doi.org/10.1016/j.ijid.2014.07.006
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).neuroborreliosis (LNB).3 Of the several Borrelia species, B. garinii
is known for its neurotropism and is associated most frequently
with LNB.4,5
The diagnosis of LNB may be challenging because the patient
may not have noticed a tick bite or erythema migrans rash. In
children in Europe, acute facial palsy and meningitis are common
manifestations of LNB, even without preceding erythema
migrans.6–8 However, these manifestations are not speciﬁc to
LNB.6,9–12 Thus, laboratory testing (serum and cerebrospinal ﬂuid
(CSF)) is needed to conﬁrm the diagnosis of LNB and exclude other
aetiologies of the neurological manifestations.
In Europe, three criteria have been suggested for the diagnosis
of deﬁnite LNB by the European Federation of Neurological
Societies: (1) neurological symptoms indicative of LNB, (2)
lymphocytic pleocytosis in CSF, and (3) demonstration ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Serum samples tested with DbpB variants shown as OD405nm/cut-off
values. For each patient or control sample, only the highest value of the three DbpB
variants is presented. All values above 1 are considered positive. The horizontal bars
represent median values. Control samples were obtained from 16 adult patients
serologically positive for Yersinia enterocolitica, Salmonella, or anti-nuclear
antibodies, and from 20 healthy adults with no proven infection. Four of the
controls were positive (range of OD/cut-off values 1.004–1.396). The cut-off is
indicated with a dashed line. LNB, neuroborreliosis; pos LNB, possible
neuroborreliosis; non LNB, other aetiology.
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lato.13 Two of these criteria should be fulﬁlled for possible LNB.
Different types of antigen have been used for ELISA and
immunoblotting methods on serum and CSF samples.5,13,14 RevA,
DbpA, DbpB, OspC, OspC peptide, VlsE, and IR6 peptide have been
studied for diagnostic purposes in LD.9,15–20 Such antigens,
produced as recombinant proteins or synthetic peptides, have
increased the speciﬁcity of laboratory testing for LD, but the
sensitivity of new antigens has been unsatisfactory. Our earlier
study on adult patients suggested that antibodies to decorin-
binding protein B (DbpB) in CSF might be beneﬁcial in the
diagnosis of LNB, especially as a marker of active infection.17
The aims of this study were to assess the occurrence of antibodies
to DbpBs in children with LNB and to evaluate the performance
of DbpBs in the diagnosis of LNB in children.
2. Materials and methods
2.1. Patient samples
Fifty-seven children (aged 2–17 years) with clinically
suspected LNB from a highly endemic area in Sweden were
included in this study. CSF and serum samples were obtained
before the start of antibiotic treatment. Laboratory testing
included CSF cell counts and the measurement of anti-ﬂagella
antibodies in serum and CSF, together with exclusion of other
neurological aetiologies.9 Based on clinical features at admission
and laboratory results, patients were divided into three groups:
conﬁrmed LNB (n = 24), possible LNB (n = 16), and non LNB
(originally not determined) (n = 17).9 In brief, the classiﬁcation
of patients with clinical symptoms indicative of LNB was as
follows: The conﬁrmed LNB group of patients had pleocytosis
(median 195, range 7–442  106 mononuclear cells/l in CSF) and
either IgG or IgM or both anti-ﬂagella antibodies in CSF. The
possible LNB group of patients had pleocytosis in CSF (median
80, range 6–301  106 cells/l in CSF) and ﬁve of them had either
IgG or IgM or both anti-ﬂagella antibodies in serum, but none in
CSF. The non LNB group of patients had no anti-ﬂagella
antibodies in CSF and no pleocytosis in CSF. One of them had
IgG and another had IgM anti-ﬂagella antibodies in serum. None
of them had erythema migrans. This group of 17 patients was
considered to have an aetiology other than LNB for the
symptoms.
The clinical characteristics of the patients have been described
in detail previously.9,21 For the anti-ﬂagella antibody ELISA, an
index value of >0.3 between serum and CSF was used (as
recommended by the manufacturer Dako (at present Oxoid),
Glostrup, Denmark) to ensure intrathecal synthesis of anti-ﬂagella
antibodies.22 The very same panel of serum and CSF samples has
been studied previously for antibodies to IR6 peptide and
recombinant proteins DbpA, OspC, and BBK32; CXL13 levels have
also been measured.9,21
2.2. Serum disease control samples
Serum samples without anti-ﬂagella antibodies were used as
disease controls (n = 36). These samples were obtained from
Finnish adult patients serologically positive for Yersinia enteroco-
litica infection (n = 3), Salmonella infection (n = 3), or anti-nuclear
antibodies (n = 10), and from healthy adults with no proven
infection (n = 20).
2.3. CSF disease control samples
CSF samples without anti-ﬂagella antibodies were used as
disease controls (n = 57). Disease control samples were availablefrom children with other neurological diseases such as conﬁrmed
viral meningitis or convulsions/epilepsy (n = 10) and from healthy
adults with no proven infection (n = 16). In addition, samples from
adult patients with neurosyphilis (n = 6), syphilis (n = 13), and viral
meningitis (n = 12) were used as disease controls.
2.4. DbpB antigens and ELISA
Recombinant antigen DbpB originated from three different
pathogenic borrelial species: B. burgdorferi sensu stricto Ia (ss),
B. afzelii A91 (afz), and B. garinii 40 (gar). The cloning, production,
and puriﬁcation of these recombinant proteins have been
described previously.23,24 ELISA tests were performed as described
previously.23 Samples from 20 healthy individuals were used to
deﬁne the cut-off value for each antigen in serum ELISA (mean plus
2 SD). Samples from 10 disease control children and from
16 healthy adults were used to deﬁne the cut-off value for each
antigen in the CSF ELISA (mean plus 3 SD). OD/cut-off values were
used to present data in the ﬁgures.
2.5. Statistics
GraphPad Prism 4 (GraphPad Software Inc., USA) and Excel XP
(Microsoft, USA) were used for calculations and illustrations.
Sensitivity was calculated from the conﬁrmed LNB and possible
LNB groups (n = 40). Speciﬁcity was calculated from healthy
adults with no proven infection and disease control samples in
CSF (n = 57) and serum (n = 36).
2.6. Ethics
The retrospective examination of serum and CSF samples was
approved by the ethics committees of Helsinki University Central
Hospital, Finland (licence number 472/E0/01) and the Faculty
of Health Sciences at Linko¨ping University, Sweden (Dnr 03-546).
3. Results
3.1. DbpB antibodies in serum
Antibodies to DbpB variants in serum ELISA were found in 13 of
the 24 patients with conﬁrmed LNB and in four of the 16 patients
with possible LNB (Figure 1, Table 1). One disease control sample
Table 1
Number of positive samples (%) to different DbpB variants in serum and in CSF ELISA
No. (%) of positive samples
n DbpB-afz DbpB-gar DbpB-ss DbpBsa
Serum
Conﬁrmed LNB 24 4 (17) 11 (46) 2 (8) 13 (54)
Possible LNB 16 0 4 (17) 0 4 (17)
Non LNB 17 2 (12) 1 (6) 2 (12) 3 (18)
Disease controls 16 0 1 (6) 0 1 (6)
Healthy adults 20 1 (5) 1 (5) 2 (10) 3 (15)
CSF
Conﬁrmed LNB 24 1 (4) 10 (42) 0 10 (42)
Possible LNB 16 1 (6) 1 (6) 0 1 (16)
Non LNB 17 0 0 0 0
Disease controls 41 2 (10) 2 (10) 2 (10) 2 (10)
Healthy adults 16 1 (6) 1 (6) 1 (6) 1 (6)
DbpB, decorin-binding protein B; afz, B. afzelii; gar, B. garinii; ss, B. burgdorferi sensu
stricto Ia; CSF, cerebrospinal ﬂuid; LNB, Lyme neuroborreliosis.
a Samples positive with at least one DbpB variant.
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healthy patient control samples were positive. The sensitivity of
the serum DbpB ELISA (all three antigens together) was 43%
(conﬁrmed NB + possible LNB) or 54% (conﬁrmed LNB only), and
the speciﬁcity was 89%. All four positive samples from the possible
LNB group were positive with the DbpB-gar variant (Table 1).
3.2. DbpB antibodies in CSF
Antibodies to DbpB variants in CSF ELISA were found in 10 of the
24 patients with conﬁrmed LNB and in one of the 16 patients with
possible LNB (Figure 2, Table 1). Three control samples were low
positive, one from a healthy individual with no proven infection
and two from patients with viral meningitis. The sensitivity of the
CSF DbpB ELISA (all three antigens together) was 28% (conﬁrmed
NB + possible LNB) or 42% (conﬁrmed LNB only), and the speciﬁcity
was 95%.
In the conﬁrmed LNB group, ﬁve of the 13 samples positive in
the serum ELISA were also positive in the CSF ELISA. In the possible
LNB group, one of the four samples positive in the serum ELISA was
positive in the CSF ELISA. The sensitivity of DbpB serum and CSF
ELISAs combined (all three antigens together) was 53% (conﬁrmed
LNB + possible LNB) or 71% (conﬁrmed LNB only).LNB pos LNB non LNB controls
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Figure 2. CSF samples tested with DbpB variants shown as OD405nm/cut-off values.
For each patient or control sample, only the highest value of the three DbpB variants
is presented. All values above 1 are considered positive. The horizontal bars
represent median values. Control samples were obtained from 10 children with
other neurological diseases and 31 adults with syphilis, neurosyphilis, or viral
meningitis, and from 16 healthy adults with no proven infection. Three control
samples were positive (range of OD/cut-off values 1.118–1.400). The cut-off is
indicated with a dashed line. LNB, neuroborreliosis; pos LNB, possible
neuroborreliosis; non LNB, other aetiology.4. Discussion
This study provides support to previous observations on the
role of B. garinii as the predominant aetiological agent of European
LNB. However, although the DbpB originating from B. garinii was
the most sensitive antigen both in serum and in CSF, the overall
sensitivity of this antigen in the laboratory diagnosis of early LNB
remained at an unsatisfactory level.
This study aimed to improve the laboratory diagnostics of early
LNB especially. Because symptoms in the early stages of infection
are usually unspeciﬁc, the diagnosis is difﬁcult to conﬁrm on
clinical grounds only.6 The interval between the initiation of
neurological symptoms and diagnostic evaluation is reported to be
shorter in children than in adults.11 Obviously, children more often
present disseminated stages of the disease earlier than adults.
Disappointingly, the present study showed that in the laboratory
diagnosis of LNB in children, serum or CSF antibodies to DbpB
appeared to be of limited value. The performance of the DbpB
ELISA assays remained inferior to routine testing with anti-ﬂagella
antibodies. The intrathecal production of DbpB antibodies was
not evaluated in this study. However, in provisional analyses,
only two of all samples from patients with conﬁrmed neuroborre-
liosis had a value 0.3 suggesting the intrathecal production
of antibodies22 (data not shown).
The sensitivity of the DbpB ELISA was highest in the children
with conﬁrmed LNB but remarkably low in those with possible
LNB. These children had a short duration of symptoms, and it
appears that DbpB antibodies are not helpful in the diagnosis of
early LNB. As a whole, both CSF and serum DbpB antibody testing
were much less sensitive compared to our previous results in
adults with LNB and adolescents with Lyme arthritis.17,25 Such
manifestations can be considered as representing more advanced
stages of the disease, and the sensitivity of the DbpB assay is
improved with the longer disease duration. In adults the median
disease course was 1 month or more,17,25 whereas in our cohort it
was 1–2 weeks. Furthermore, it has been reported that the
intrathecal synthesis of anti-Borrelia antibodies increases with
the duration of the disease.26,27 The delay between the ﬁrst
appearance of symptoms and diagnostic evaluation, as well as
the clinical outcome of the disease, have all been reported to be
associated with the level of CSF pleocytosis.28,29
The low sensitivity of DbpB antibody testing can also be
explained in part by the heterogeneity of DbpB variants between
the different Borrelia species.23 Among the three DbpB antigens,
the recombinant protein originating from B. garinii outperformed
the other variants in the diagnosis of LNB. This is in line with
our earlier study on the diagnosis of adult patients with LNB.17 Of
the B. burgdorferi sensu lato species, B. garinii is not detected in
the USA where LNB is uncommon.30,31 In Europe, LNB in most cases
is caused by B. garinii.4,5
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